Rafael Fonseca: One of the most impressive aspects of more effective front line therapies in multiple myeloma

Rafael Fonseca shared on X:

“One of the most impressive aspects of more effective front-line therapies in multiple myeloma is how long the benefit can last. for IMROZ the TTNT is quite long with only ~20% of patients starting a new line at 5 years.”

Source: Rafael Fonseca/X

Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing  in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment.

He has led research on genetic markers in myeloma. Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.